rawfin.tv
InflaRx Reports Favorable Preclinical Data for Oral C5aR1 Inhibitor Izicopan
TechnologystocksAI Generated

InflaRx Reports Favorable Preclinical Data for Oral C5aR1 Inhibitor Izicopan

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

InflaRx (IFRX) announced new preclinical data for its oral C5aR1 inhibitor, izicopan. The data indicates that the drug generates low levels of reactive metabolites, supporting its safety profile.

biotechdrug developmentpreclinical dataizicopanpharmaceuticals

Related Articles

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks